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Abstract
The  CYP2D6 gene is responsible for the majority of tamoxifen
metabolism. Recent compelling, yet limited data have determined
that postmenopausal women who carry a functional polymorphism
in the CYP2D6 gene have a worse clinical outcome than women
who have a wild-type genotype. In this commentary we discuss the
level of evidence needed to change clinical practice and whether
CYP2D6 genotyping is appropriate for all women considering
tamoxifen as part of their adjuvant therapy.
The emerging field of pharmacogenetics holds the promise
for determining effective treatment options and improving
outcomes. It also raises the issues of when and how
practicing physicians decide to incorporate emerging science
into their practice. The case of tamoxifen and cytochrome
P450 CYP2D6 genotyping illustrates how this problem can
be approached by evaluating the risks and benefits of testing
in specific subsets of patients.
Recent research, including prospective studies, evaluating
CYP2D6 genetics and tamoxifen metabolism and a
retrospective analysis of CYP2D6 genetics and outcomes
from a prospective trial strongly suggest that the CYP2D6
genotype, as well as the use of CYP2D6 inhibitors, is
predictive of tamoxifen efficacy [1-4]. At the American
Society of Clinical Oncology (ASCO) Clinical Science
Symposium in June 2006, Knox and colleagues [4] presented
compelling data from a retrospective cohort of 256
postmenopausal, hormone-positive patients treated with
tamoxifen alone in the adjuvant setting. They found that
certain functional polymorphisms of CYP2D6, as determined
for a subset of 171 patients, correlated with worse relapse-
free survival and disease-free survival. At this same
symposium, Grabinski and colleagues [5] demonstrated that
patients with specific functional CYP2D6 polymorphisms
produce extremely low levels of active tamoxifen metabolites.
On 18 October 2006 the FDA Clinical Pharmacology
Subcommittee unanimously agreed that this new clinical
evidence demonstrates that the CYP2D6 gene is an
important predictor of tamoxifen efficacy.
The CYP2D6 enzyme is part of the P450 enzyme system and
is responsible for metabolizing tamoxifen to its most active
form, endoxifen. Humans all inherit two alleles for the
CYP2D6 gene, one from each parent. Each allele may be
normal (designated ‘wt’) or variant type (designated ‘vt’).
Thus, genotypically, an individual may be homozygous wild
type (wt/wt), heterozygous (wt/vt), or homozygous variant
(vt/vt). Each of these genotypes may lead to variable
metabolism of drugs like tamoxifen. Individuals with CYP2D6
polymorphisms that render the gene product inactive, termed
‘poor metabolizers’, produce endoxifen at very low levels
[2,5]. Approximately 7% to 10% of the Caucasian population
are poor metabolizers. The evidence presented at ASCO
suggests these poor metabolizer patients are at increased
risk of breast cancer recurrence because of lack of tamoxifen
efficacy resulting from their CYP2D6 genotype. In addition,
certain inhibitors of the CYP2D6 enzyme, such as the
selective serotonin reuptake inhibitors, which are frequently
given to breast cancer patients to combat hot flashes and
treat depression, may result in altered tamoxifen activity, and
lead to poorer clinical outcomes [2,4].
These extraordinarily important findings have resulted from
analyses of only a few hundred patients and are
retrospectively derived; however, they may potentially affect
many thousands of women worldwide who take adjuvant
tamoxifen as part of therapy for breast cancer.
Under what circumstances should patients considering
tamoxifen as an adjuvant therapy be tested for CYP2D6 and
under what circumstances should patients taking tamoxifen
avoid potent inhibitors of CYP2D6? There is concern over
the widespread clinical use of CYP2D6 genotyping to guide
decision-making about adjuvant therapies without prospec-
tively validated data and because of the relatively small
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number of patients from which the outcomes in tamoxifen-
treated patients have been derived. The problem with such
retrospective data is that it is impossible to exclude the
possibility that some factor other than the factor analyzed (in
this case, CYP2D6 genotype) may account for or contribute
to the imbalance found in the outcomes. Prospective trials
can attempt to control for such confounding imbalances
through randomization and other techniques. When the
potential benefits of a proposed therapy are large, as they are
in the case of adjuvant tamoxifen, the standards of validation
for a predictive test used to determine whether or not that
therapy should be provided must be high. This is true unless
there are other, acceptable alternatives that provide similar
potential benefits, as in the case for postmenopausal women
contemplating tamoxifen as part of their adjuvant hormonal
therapy and for women on tamoxifen who are taking selective
serotonin reuptake inhibitors, such as paroxetine and
fluoxetine, that are potent inhibitors of CYP2D6.
Postmenopausal, hormone-positive breast cancer patients
contemplating tamoxifen as part of their adjuvant hormonal
therapy have a clear choice between an aromotase inhibitor
(AI) for five years or sequencing tamoxifen and an AI [6,7].
Because both alternatives are acceptable and currently widely
used in practice, providing postmenopausal women with
information about their CYP2D6 genotype will allow them to
make an informed choice about their adjuvant hormonal
treatment and, most importantly, avoid the potential of taking a
therapy that may lack efficacy when there are acceptable
alternatives. Because AI treatment provides a benefit of equal
if not superior magnitude to tamoxifen in postmenopausal
women, poor metabolizers will be able to avoid tamoxifen by
taking an AI and, consequently, decrease their risk of breast
cancer recurrence. The Breast Intergroup has tentatively
approved a randomized study to further evaluate the role of
CYP2D6 status and treatment with an AI upfront versus
tamoxifen followed by an AI in postmenopausal women.
Pre- and perimenopausal women who are considering taking
tamoxifen in an adjuvant setting do not have such alternatives.
More prospectively derived outcomes data are needed to
confidently extend the recommendation for CYP2D6 geno-
typing to these patients. Although a reasonable alternative to
tamoxifen for these women might be an AI in addition to
ovarian suppression, no randomized trials have demonstrated
equivalence between these two alternatives, although the
Suppression of Ovarian Function Trial (SOFT) is currently
addressing this question [8]. In addition, ovarian suppression
has undesirable side effects, may affect fertility, and is
irreversible if surgical oophorectomy is performed. Thus, in
contrast to the situation for postmenopausal patients, proven,
equivalent alternatives to tamoxifen do not exist. For these
reasons we conclude that CYP2D6 genotyping should not
be routinely performed as a predictive test used to make
treatment decisions for pre- and perimenopausal women until
we have more definitive data.
Conclusions
Our ethical responsibility to our patients is to carefully
balance risks and benefits in helping them to make decisions.
At times, we are in a position of uncertainty with respect to
the magnitude of risks as well as benefits. In such cases,
especially when the magnitude of potential benefit is large (as
it is in the case of tamoxifen) and the magnitude of risk is
uncertain, we should err on the side of caution and continue
to recommend therapies for which there is strong or definitive
evidence. This responsibility can sometimes require waiting
until a therapy or test has prospectively proven efficacy
before prescribing it to our patients, or until there are proven
alternatives available.
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